跳至主要内容
临床试验/NCT03141632
NCT03141632已完成2 期

Effects of GLP-1 Analogues on Fluid Intake in Healthy Volunteers - "The GATE-Study"

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2016年10月17日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
17
试验地点
1
主要终点
Fluid intake

研究概览

简要总结

The aim of this study is to elucidate whether GLP-1 analogues influence not only appetite but also thirst perception. It is hypothesized that GLP-1 analogues reduce fluid intake in healthy volunteers compared to Placebo.

详细描述

GLP-1 analogues are well known to stimulate glucose-induced insulin secretion and to reduce energy intake. Recent findings from animal and human studies suggest a role of GLP-1 in regulating water and salt homeostasis. GLP-1 has been shown to reduce fluid intake after an oral salt load or during a meal - pointing to a hypodipsic effect. The aim of this study is to elucidate whether these putative hypodipsic properties of GLP-1 analogues reduce fluid intake in healthy volunteers compared to placebo assessed during an evaluation visit of 8 hours.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Double blind study

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 to 65 years

排除标准

  • Known or probable central or nephrogenic Diabetes insipidus, based on patient's history
  • Polyuria secondary to diabetes mellitus, hypokalemia, hypercalcemia
  • Primary Polydipsia, defined as more than 4 liters fluid intake per day
  • BMI <18 or >30kg/m2
  • Pregnancy
  • Previous treatment with GLP-1 agonists within the last 3 month
  • History of pancreatitis
  • Severe renal insufficiency (eGFR (CKD EPI) <30 ml/min/1,73 m2)

研究组 & 干预措施

Dulaglutide

Active Comparator

Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.

干预措施: Dulaglutide (Drug)

Placebo

Placebo Comparator

0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.

干预措施: Placebo (Other)

结局指标

主要结局

Fluid intake

时间窗: 8 hours

Fluid intake (ml) during an evaluation visit

次要结局

  • Urine volume(24 hours)
  • Urinary sodium(24 hours)
  • Electrolytes(3 timpoints during 8 hours)
  • Urine electrolytes(3 timpoints during 8 hours)
  • copeptin(3 timpoints during 8 hours)
  • renin(3 timpoints during 8 hours)
  • Thirst(8 hours)
  • aldosterone(3 timpoints during 8 hours)
  • Water and Salt(3 timpoints during 8 hours)
  • GLP-1(3 timpoints during 8 hours)
  • Hypothalamus Pituitary Adrenal Axis (HPA)(24 hours)
  • circadian rhythm(16 hours)
  • salivary cortisol(16 hours)
  • ACTH(16 hours)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验